BDNF and major depressive disorder: These findings suggested that NT-3 could be a potential novel pharmaceutical target for MDD due to its effects on the HPA axis, synaptic plasticity and neurogenesis regulation, BDNF signaling stimulation, and monoamine neurotransmitters [53].